CVSC Cardiovascular Sciences Inc (CE)

Cardiovascular Sciences, Inc. (PINK SHEETS: CVSC) has been quite busy, rapidly approaching a launch of its antioxidant, anti-aging cell renewal formula and other select health related products. Initial samples of the supplement have been delivered to the Company�s corporate offices and have exceeded the Company�s expectations. The supplement has also generated considerable interest from several companies that market such products directly to physicians. Other products complementary to the antioxidant have been delivered to the fulfillment center. A service agreement has been signed with United Fulfillment Solutions, Inc. located in a large underground complex near St. Louis and products are currently being delivered. Robert Lawrence, COO and co-owner of UFSI, states, �We are excited that Cardiovascular Sciences has chosen United Fulfillment as their order fulfillment provider. Being located underground, we are able to maintain Cardiovascular�s products in a naturally climate controlled environment in the most eco-friendly way available. Utilizing an underground fulfillment center to support Cardiovascular Sciences� distribution needs results in a savings of over 63% on energy usage and eliminates any risk that other centers might experience in the event of the failure of their climate control equipment.� Dr. Larry Hooper, CEO of Cardiovascular Sciences, Inc. explains, �We are currently arranging and coordinating our new website with the fulfillment center�s software and that of various financial institutions. We expect to beta test the ordering process within the next few days and plan a full roll out the first week of August. Watch for press releases as we accomplish these final stages before going live.� About Cardiovascular Sciences Cardiovascular Sciences, Inc. is an advanced medical device company, with a primary focus of developing a novel technology platform to address problems of post-surgical adhesions. Adhesions and their complications are a significant problem worldwide for a broad range of specialists, including general and cardiothoracic surgeons, orthopedic, plastic, ophthalmologic and otolaryngology specialists to name a few. In addition, the veterinary field has a tremendous need for a product that can prevent similar problems in a variety of animals. The Company's unique materials and processes promise a more cost-effective and decidedly more efficient and capable means to deal with a problem that has been so devastating to so many. Current sponsored research at the UCF and previously at other institutions indicate that the Company is on the right path and progressing well. In addition to the anti-adhesion technology, the Company owns technology in a variety of other areas, yielding a diversified portfolio with projects in various stages of development. Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties, and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.